rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lantheus Holdings, Inc.

LNTH · Nasdaq

Health CareDiagnostics & LabsIn trend

LNTH stood above a rising 150-day average in 32 of the last 52 weekly readings, including each of the last 32 weeks. It is 3.7% above that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
32 in a row
Industry in uptrend
48% -2 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
4
Institutions holding
425 (+50)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct
20%38%55%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$368.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k28 Jan 2025filed 11 Feb 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k13 Jan 2025filed 11 Feb 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k8 Jan 2025filed 11 Feb 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k7 Jan 2025filed 11 Feb 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders425+50 on the quarter
New · exited89 · 38
Reported value$8.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20268,397,642$931.6M+214,449+2.6%
FARALLON CAPITAL MANAGEMENT, L.L.C.unchanged · filed 14 Aug 20265,583,479$619.4M00.0%
Jupiter Topco LLCnew · filed 14 Aug 20265,188,416$575.6M+5,188,416
FMR LLCreduced · filed 13 Aug 20263,879,971$430.4M-746,482−16.1%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20263,238,471$359.3M+64,197+2.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,932,214$325.3M+17,900+0.6%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20262,816,547$312.5M+1,035,441+58.1%
STATE STREET CORPadded · filed 7 Aug 20262,500,696$277.4M+70,893+2.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,841,367$204.3M+75,415+4.3%
MORGAN STANLEYadded · filed 13 Aug 20261,726,303$191.5M+79,840+4.8%
31 Mar 2023 – 30 Jun 2026
321394466Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Robert J. Marshall Jr. Company insiderCFO and Treasurer · last 31 Aug 20260 · 26
Kimberly Brown Company insiderChief Accounting Officer · last 17 Aug 20260 · 0
Ludger Dinkelborg Company insiderOfficer · last 17 Aug 20260 · 0
Gary J. Pruden Company insiderDirector · last 14 May 20260 · 2
Gerard Ber Company insiderDirector · last 14 May 20260 · 2
Heinz Christoph Maeusli Company insiderDirector · last 14 May 20268 · 1
James H. Thrall Company insiderDirector · last 14 May 20260 · 3
Julia Marie Eastland Company insiderDirector · last 14 May 20260 · 0
Julie McHugh Company insiderDirector · last 14 May 20260 · 8
Mary Anne Heino Company insiderExecutive Chair and CEO · last 14 May 20260 · 45
Minnie Baylor-Henry Company insiderDirector · last 14 May 20260 · 1
Phuong Khanh Morrow Company insiderDirector · last 14 May 20260 · 0

Same industry

CDNA CareDxLeading+83%
XGN ExagenLeading+49%
NTRA NateraLeading+46%
PSNL PersonalisLeading+35%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$541K
Latest20 Jul 2026

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202561.1%
Operating profit marginFY 2025 · to 31 Dec 202520.2%
Return on capital employedFY 2025 · to 31 Dec 202516.4%
Cash conversionFY 2025 · to 31 Dec 2025167%
Debt to equityFY 2025 · to 31 Dec 20250.00×
Research spendFY 2025 · to 31 Dec 202511.5%
Share count trendFY 2025 · to 23 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$359.1M

Analyst forecasts

No analyst forecasts yet.